Skip to main content
Xbrane Biopharma logo

Xbrane Biopharma — Investor Relations & Filings

Ticker · XBRANE ISIN · SE0007789409 LEI · 5493008DKD05APTKQO39 ST Manufacturing
Open in API
Filings indexed 359 across all filing types
Latest filing 2025-05-08 Interim / Quarterly Rep…
Country SE Sweden
Listing ST XBRANE

About Xbrane Biopharma

https://xbrane.com/en/

Xbrane Biopharma is a biotechnology company that specializes in the development of biosimilars—follow-on versions of approved biological drugs. The company's mission is to enhance the accessibility of biological treatments for serious diseases by creating more affordable alternatives. Xbrane utilizes a patented platform technology and efficient manufacturing systems, employing both bacterial and mammalian cells, to achieve lower production costs. Its development pipeline includes several biosimilar candidates, with a key product being a ranibizumab biosimilar.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report January – March 2025' and contains comprehensive financial data, including a financial summary table, income statements, and detailed management commentary on business performance for the first quarter of 2025. It meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial analysis and actual financial statements for a period shorter than a full fiscal year. Q1 2025
2025-05-08 English
Announcement from the annual general meeting in Xbrane Biopharma AB
AGM Information Classification · 99% confidence The document explicitly states it is an "Announcement from the annual general meeting 2025 (the 'AGM') of Xbrane Biopharma AB". It details the resolutions passed regarding the adoption of financial statements, allocation of profit (no dividend), discharge from liability, election of the board and auditor, remuneration, and adoption of governance principles. These contents are the direct outcomes and summary of the Annual General Meeting proceedings. Therefore, the appropriate classification is AGM Information (AGM-R). The document length is moderate, but its content is a direct summary of the meeting, not just an announcement that a report is available (which would suggest RPA or RNS).
2025-05-05 English
Kommuniké från årsstämma i Xbrane Biopharma AB
AGM Information Classification · 99% confidence The document is explicitly titled "Kommuniké från årsstämma i Xbrane Biopharma AB" (Communiqué from the Annual General Meeting in Xbrane Biopharma AB). It details the decisions made by the shareholders regarding the approval of financial statements, dividend disposition, election of the board and auditor, remuneration, and approval of compensation guidelines. These are all standard resolutions passed at an Annual General Meeting (AGM). Although it is a communiqué summarizing the results, the core subject matter is the AGM proceedings and outcomes, making 'AGM Information' (AGM-R) the most appropriate classification, as it contains the decisions made during the meeting.
2025-05-05 Swedish
Announcement from extra general meeting in Xbrane Biopharma AB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement regarding the resolutions passed at an 'extra general meeting' (EGM) of Xbrane Biopharma AB. It specifically details the approval of an asset sale transaction. While it mentions the meeting, it functions as a declaration of the results of the voting process at that meeting. Therefore, it falls under the category of Declaration of Voting Results & Voting Rights Announcements.
2025-04-14 English
Kommuniké från extra bolagsstämma i Xbrane Biopharma AB
M&A Activity Classification · 95% confidence The document is a 'Kommuniké från extra bolagsstämma' (Communiqué from an Extraordinary General Meeting) which details the results of shareholder votes regarding the sale of assets to Alvotech. While it contains information about an M&A transaction, the primary purpose of the document is to report the outcome of a formal shareholder meeting. According to the filing definitions, 'DVA' (Declaration of Voting Results) is the most accurate classification for the results of a general meeting. Although it mentions the transaction, it is not a standalone M&A announcement document but rather the official record of the meeting's voting outcome.
2025-04-14 Swedish
NOTICE OF ANNUAL GENERAL MEETING IN XBRANE BIOPHARMA AB
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of Annual General Meeting' for Xbrane Biopharma AB. It contains the agenda, instructions for shareholder participation (in-person, proxy, and advance voting), and details on proposed resolutions such as board elections and remuneration. This document is a standard proxy solicitation and meeting notice provided to shareholders to inform them of the upcoming AGM and request their participation/votes. It fits the definition of a Proxy Solicitation & Information Statement (PSI).
2025-04-02 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.